Cambridge Investment Research Advisors, Inc. Axsome Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$21.74 - $46.75 $207,073 - $445,293	-9,525 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$23.7 - $41.39 $45,385 - $79,261	-1,915 Reduced 16.74%	9,525 $394,000
Q3 2021 Nov 02, 2021	BUY	$19.91 - $68.26 $77,748 - $266,555	3,905 Added 51.82%	11,440 $377,000
Q2 2021 Aug 10, 2021	SELL	$50.63 - $73.5 $107,082 - $155,452	-2,115 Reduced 21.92%	7,535 $508,000
Q1 2021 May 07, 2021	BUY	$55.91 - $81.44 $539,531 - $785,896	9,650 New	9,650 $546,000
Q1 2020 May 08, 2020	SELL	$41.2 - $101.31 $107,243 - $263,709	-2,603 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$16.71 - $106.24 $134,883 - $857,569	-8,072 Reduced 75.62%	2,603 $269,000
Q3 2019 Nov 06, 2019	SELL	$20.24 - $29.16 $4,554 - $6,561	-225 Reduced 2.06%	10,675 $216,000
Q2 2019 Aug 15, 2019	BUY	$13.46 - $25.75 $146,714 - $280,675	10,900 New	10,900 $0

Others Institutions Holding AXSM

# of Institutions

327

Shares Held

38M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $4.56B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account